Finance

Finance

Analyst picks & changes
CompanyBankAnalystCoverageOpinionWk chg9/25 cls
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT)H.C. WainwrightEd ArceNewBuy11%$5.16
Arce initiated coverage with a $15 target, saying that Conatus' emricasan is a "highly

Read the full 258 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE